Get started
Author

Francesca Negri

Observed names: F Negri, F V Negri, F. NEGRI, F. Negri, F.V. Negri, Francesca V Negri, Francesca V. Negri, Francesca Virginia Negri, Negri FV, Negri, Francesca
Observed institutions: University of Parma, University of Udine, Royal Marsden NHS Foundation Trust, University of Pavia, Istituto Giannina Gaslini, Royal Marsden Hospital, National Cancer Institute, Azienda Ospedaliero-Universitaria Cagliari, National Cancer Institute, Ospedale di Parma, National Cancer Institute, Istituti di Ricovero e Cura a Carattere Scientifico, University of Genoa
ORCID: 0000-0002-5847-3623
Observed ORCID: 0000-0002-5847-3623
OpenAlex ID: A5012497531
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
2018 · Lorenza Rimassa, Eric Assenat, et al. · The Lancet Oncology · 351
Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis
2004 · Roberta Castriconi, Alessandra Dondero, et al. · Proceedings of the National Academy of Sciences · 294
Microsatellite instability in colorectal cancer.
2018 · Gian Luigi De' Angelis, Lorena Bottarelli, et al. · Acta bio-medica dell'Ateneo parmense/Acta biomedica · 163
PDF
Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer
2005 · F.V. Negri, A. Wotherspoon, et al. · Annals of Oncology · 157
Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
2011 · C Bozzetti, F V Negri, et al. · British Journal of Cancer · 152
PDF
Immunotherapy for colorectal cancer: where are we heading?
2017 · Debora Basile, Silvio Ken Garattini, et al. · Expert Opinion on Biological Therapy · 99
PDF
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
2016 · Andrea Casadei Gardini, Emanuela Scarpi, et al. · Oncotarget · 93
PDF
PTEN status in advanced colorectal cancer treated with cetuximab
2009 · F V Negri, C Bozzetti, et al. · British Journal of Cancer · 83
PDF
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy
2007 · F V Negri, N Campanini, et al. · British Journal of Cancer · 83
PDF
Both CD133+ and CD133– medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK‐mediated cytotoxicity
2007 · Roberta Castriconi, Alessandra Dondero, et al. · European Journal of Immunology · 78
PDF
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
2009 · Mario Scartozzi, Italo Bearzi, et al. · BMC Cancer · 72
PDF
Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases
2003 · Claudio Gambini, Massimo Conte, et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 71
A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study
2019 · Fotios Loupakis, Rossana Intini, et al. · European Journal of Cancer · 69
PDF
Molecular classifications of gastric cancers: Novel insights and possible future applications
2017 · Silvio Ken Garattini, Debora Basile, et al. · World Journal of Gastrointestinal Oncology · 66
PDF
Expression of pERK and VEGFR ‐2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment
2015 · Francesca V. Negri, Barbara Dal Bello, et al. · Liver International · 56
KRAS: A Druggable Target in Colon Cancer Patients
2022 · Francesca Negri, Lorena Bottarelli, et al. · International Journal of Molecular Sciences · 54
PDF
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma
2003 · Cecilia Bozzetti, Nicola Personeni, et al. · Cancer · 44
PDF
GDNF deficit in Hirschsprung's disease
1998 · G Martucciello, H Thompson, et al. · Journal of Pediatric Surgery · 43
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
2016 · Valentina Fanotto, Elena Ongaro, et al. · Oncotarget · 39
PDF
Genetic abnormalities in adolescents and young adults with neuroblastoma: A report from the Italian Neuroblastoma Group
2015 · Katia Mazzocco, Raffaella Defferrari, et al. · Pediatric Blood & Cancer · 39
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?
2017 · Giuseppe Aprile, Francesca V. Negri, et al. · Critical Reviews in Oncology/Hematology · 32
Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma
2008 · Annalisa Pezzolo, Elena Rossi, et al. · Neuro-Oncology · 30
PDF
Prognostic and Predictive Cross-Roads of Microsatellite Instability and Immune Response to Colon Cancer
2020 · Luigi Laghi, Francesca Negri, et al. · International Journal of Molecular Sciences · 29
PDF
A Retrospective Study of Resection of Pulmonary Metastases in Patients wit Advanced Colorectal Cancer: The Development of a PreoperativeChemotherapy Strategy
2004 · Francesca Negri, Antonino Musolino, et al. · Clinical Colorectal Cancer · 29
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy
2013 · F V Negri, A Musolino, et al. · The Pharmacogenomics Journal · 25
Works count: 109
Citation count: 2,699
H-index: 25
I10-index: 44
Year
Topic
Type